TY - JOUR
T1 - Impact of pain and functional impairment in US adults with haemophilia
T2 - Patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study
AU - Kempton, C. L.
AU - Recht, M.
AU - Neff, A.
AU - Wang, M.
AU - Buckner, T. W.
AU - Soni, A.
AU - Quon, D.
AU - Witkop, M.
AU - Boggio, L.
AU - Gut, R. Z.
AU - Cooper, D. L.
N1 - Funding Information:
The P-FiQ study was managed by Quintiles Real World and Late Phase, Boston, Massachusetts, and Rockville, Maryland, with statistical analyses provided by Jennifer James, Senior Biostatistician, and was supported financially by Novo Nordisk Inc. Writing assistance was provided by Anna Abt, PhD, of ETHOS Health Communications in Newtown, Pennsylvania, and was supported financially by Novo Nordisk Inc., Plainsboro, New Jersey, in compliance with international Good Publication Practice guidelines.
Funding Information:
C. Kempton has served as a consultant for Baxalta, Hoffmann-La Roche, Biogen, CSL Behring and Kedrion and received grant/research support from Novo Nordisk. M. Recht has received grant/ research support from Baxter, Biogen Idec, Novo Nordisk and Pfizer and served as a consultant to Kedrion and Novo Nordisk. N. Neff has served on advisory boards for Kedrion and Novo Nordisk. M. Wang has served as a consultant for Baxalta, Biogen, CSL Behring, LFB and Novo Nordisk. T. Buckner has served as a consultant for Baxalta, Genentech and Novo Nordisk. A. Soni has been on speakers bureaus for CSL Behring and Novo Nordisk. D. Quon is on advisory boards for Baxalta, Bayer, Biogen and Novo Nordisk and speakers bureaus for Baxalta, Biogen, CSL Behring, Grifols and Novo Nordisk. M. Witkop has received grant funding from Pfizer, is on advisory boards for Baxter BioScience, CSL Behring, Novo Nordisk, Octapharma and Pfizer and is on the speakers bureau for Novo Nordisk. L. Boggio is a consultant for Baxter, Bayer, Biogen, CSL Behring, Novo Nordisk and Octapharma and has received research support from Baxter (Baxalta), Bayer, Biogen, CSL Behring, Novo Nordisk, Octapharma, OPKO and Selexys. R. Gut is an employee of Novo Nordisk Inc. D. Cooper is an employee of Novo Nordisk Inc.
Publisher Copyright:
© 2017 John Wiley & Sons Ltd
PY - 2018/3
Y1 - 2018/3
N2 - Introduction: Standardized and disease-specific patient-reported outcome (PRO) instruments assessing pain, functional impairment and health-related quality of life (HRQoL) in people with haemophilia (PWH) have been used in studies, but infrequently in comprehensive care settings for individual assessment or treatment planning. Aim: To assess the impact of pain and functional impairment on HRQoL in PWH. Methods: P-FiQ enrolled 381 adult PWH with a history of joint pain/bleeding and included 5 PROs and a clinical joint evaluation (Hemophilia Joint Health Score v2.1 [HJHS]). Results: Median age was 34 years; 49.9% reported a history of joint procedure or surgery. On EQ-5D-5L, most reported problems with mobility (61.4%), usual activities (53.2%) and pain/discomfort (76.1%). On Brief Pain Inventory v2 Short Form, median worst pain (range 0-10) was 6, least pain 1, average pain 3 and current pain 2. Ankles were most frequently reported as the most painful joints (37.4%), followed by knees (23.7%) and elbows (18.9%). On International Physical Activity Questionnaire, 51% reported no activity in the prior week. On SF-36v2 health survey, median subscores were worse for 4 physical health domains vs 4 mental health domains. Among Hemophilia Activities List domains (range 0 [worst]-100 [best]), functions of the legs (median, 66.7) and lying/sitting/kneeling/standing (median, 67.5) were most impacted and self-care least impacted (median, 100.0). On HJHS, ankle scores (median, 6.0; range, 0-40) were worse than elbow/knee scores (median, 4.0/4.0). Results were consistent across PROs/HJHS. Conclusion: Data demonstrate challenges of predominantly ankle/knee pain and lower extremity functional impairment in US adult PWH, affecting HRQoL across PROs/HJHS.
AB - Introduction: Standardized and disease-specific patient-reported outcome (PRO) instruments assessing pain, functional impairment and health-related quality of life (HRQoL) in people with haemophilia (PWH) have been used in studies, but infrequently in comprehensive care settings for individual assessment or treatment planning. Aim: To assess the impact of pain and functional impairment on HRQoL in PWH. Methods: P-FiQ enrolled 381 adult PWH with a history of joint pain/bleeding and included 5 PROs and a clinical joint evaluation (Hemophilia Joint Health Score v2.1 [HJHS]). Results: Median age was 34 years; 49.9% reported a history of joint procedure or surgery. On EQ-5D-5L, most reported problems with mobility (61.4%), usual activities (53.2%) and pain/discomfort (76.1%). On Brief Pain Inventory v2 Short Form, median worst pain (range 0-10) was 6, least pain 1, average pain 3 and current pain 2. Ankles were most frequently reported as the most painful joints (37.4%), followed by knees (23.7%) and elbows (18.9%). On International Physical Activity Questionnaire, 51% reported no activity in the prior week. On SF-36v2 health survey, median subscores were worse for 4 physical health domains vs 4 mental health domains. Among Hemophilia Activities List domains (range 0 [worst]-100 [best]), functions of the legs (median, 66.7) and lying/sitting/kneeling/standing (median, 67.5) were most impacted and self-care least impacted (median, 100.0). On HJHS, ankle scores (median, 6.0; range, 0-40) were worse than elbow/knee scores (median, 4.0/4.0). Results were consistent across PROs/HJHS. Conclusion: Data demonstrate challenges of predominantly ankle/knee pain and lower extremity functional impairment in US adult PWH, affecting HRQoL across PROs/HJHS.
KW - functional impairment
KW - haemophilia
KW - joint health
KW - pain
KW - patient-reported outcome
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85042693123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042693123&partnerID=8YFLogxK
U2 - 10.1111/hae.13377
DO - 10.1111/hae.13377
M3 - Article
C2 - 29218759
AN - SCOPUS:85042693123
SN - 1351-8216
VL - 24
SP - 261
EP - 270
JO - Haemophilia
JF - Haemophilia
IS - 2
ER -